<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394823</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489ADE24</org_study_id>
    <nct_id>NCT00394823</nct_id>
  </id_info>
  <brief_title>VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients</brief_title>
  <official_title>A Randomized, Open-label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Measures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of supportive measures on the drug
      adherence of patients with essential hypertension
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug adherence in patients (daily proportion of patients taking one tablet of the prescribed hypertensive therapy as prescribed)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance and persistence between randomized groups over time.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess discrepancies between pill counts, Morisky questionnaire and electronic monitoring to estimate patient adherence to prescribed therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the relation between drug exposure and BP reduction.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the relation between drug exposure and the likelihood to switch to valsartan 160 mg plus HCTZ 12.5 mg</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of valsartan 160 mg and valsartan 160 mg plus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCTZ 12.5 mg.</measure>
  </secondary_outcome>
  <enrollment type="Actual">206</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Set of supportive tools/measures vs. standard care</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients &gt;= 18 years

          -  Females must be either post-menopausal for one year, surgically sterile or using
             effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine
             device, hormonal contraceptives).

          -  Patients with mild essential hypertension: Systolic blood pressure ≥ 140 mmHg and &lt;
             170 and/or diastolic blood pressure ≥ 90 mmHg and &lt; 105 mmHg&quot;

        Exclusion Criteria:

          -  Moderate and severe hypertension

          -  Pregnant or nursing women

          -  A history of cardiovascular disease, including angina pectoris, myocardial infarction,
             coronary artery bypass graft, percutaneous transluminal coronary angioplasty,
             transient ischemic attack, stroke, and heart failure NYHA II - IV

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Basel</last_name>
    <role>Study Chair</role>
    <affiliation>+41 61 324 1111</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2526</url>
    <description>Results for CVAL489ADE24 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <keyword>Hypertension, valsartan, compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

